PANAVIR (5 ampoules of 5ml) - antiviral and immunomodulatory agent

PANAVIR (5 ampoules of 5ml). The active substance is the polysaccharides of the shoots of potato (Solanum tuberosum). Panavir® - purified extract of the shoots of the plant Solanum tuberosum; the main active ingredient is a hexose glycoside, consisting of glucose, rhamnose, arabinose, mannose, xylose, galactose, uronic acids. It increases the body's nonspecific resistance to various infections and promotes the induction of alpha and gamma interferons by blood leukocytes.

Tests have shown the absence of mutagenic, teratogenic, carcinogenic, allergenic and embryotoxic effects. In preclinical studies on laboratory animals, no negative effects on reproductive function and fetal development have been established. It has anti-inflammatory properties in experimental models of exudative edema, chronic proliferative inflammation and in the test of pseudo-allergic inflammatory response to concanavalin A.

An analgesic effect was shown on models of neurogenic pain and pain caused by the inflammatory process and thermal irritation. Has an antipyretic effect. Neuroprotective properties are shown on the model of parkinsonian syndrome caused by the systemic administration of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

It has the ability to improve the function of the retina and optic nerve. It has wound-healing properties in conditions of a model of gastric ulcer.

Direction:

antiviral and immunomodulatory preparation.

Ingredients:

Active substance: Panavir® (potato shoots total polysaccharides) - 200 mcg;

Excipients: sodium chloride - 0.045 g, water for injection - up to 5 ml.

Indications:

• Herpesvirus infections of various localization (including recurrent genital herpes, herpes zoster and ophthalmic herpes).
• Secondary immunodeficiency states on the background of infectious diseases.
• Cytomegalovirus infection, including in patients with recurrent miscarriage.
• It is used in women with chronic viral infection and interferon deficiency in the preparation for pregnancy.
• Chronic cytomegalovirus infection in the acute stage in pregnant women in the II and III trimester as part of complex therapy.
• Papillomavirus infection (anogenital warts) as part of complex therapy.
• Peptic ulcer of the stomach and duodenum in patients with long-term scarring ulcers and symptomatic ulcers of the gastroduodenal zone as part of complex therapy.
• Tick-borne encephalitis in order to reduce the viral load and relieve neurological symptoms (anisoreflexia, decreased reflexes, painful exit points of the cranial nerves, nystagmus) as part of complex therapy.
• Rheumatoid arthritis combined with herpesvirus infection in immunocompromised patients (to enhance the analgesic and anti-inflammatory effect of the main therapy), as part of complex therapy.
• SARS and influenza as part of complex therapy.
• Panavir® is used in the complex therapy of chronic bacterial prostatitis.

Dosage:

Panavir® should be administered slowly intravenously. The therapeutic dose of the preparation is 200 mcg of the active substance (the contents of one ampoule or vial).

For the treatment of herpesvirus infections and tick-borne encephalitis, it is used twice with an interval of 48 or 24 hours. If necessary, the course of treatment can be repeated after 1 month.

For the treatment of cytomegalovirus and papillomavirus infections, it is used three times during the first week with an interval of 48 hours and twice during the second week with an interval of 72 hours.

For the treatment of chronic cytomegalovirus infection in the acute stage in pregnant women in the II and III trimester, it is used three times during the first week with an interval of 48 hours and twice during the second week with an interval of 72 hours.

For the treatment of peptic ulcer of the stomach and duodenum in the acute phase and symptomatic ulcers of the gastroduodenal zone, 5 intravenous injections are used every other day for 10 days.

For the treatment of rheumatoid arthritis, combined with herpesvirus infection in immunocompromised patients, 5 intravenous injections are used with an interval of 24-48 hours, if necessary, repeat the course after 2 months.

For the treatment of SARS and influenza, 2 intravenous injections are used with an interval of 18-24 hours.

For the treatment of patients with chronic bacterial prostatitis, 5 intravenous injections are used with an interval of 48 hours.

Contraindications for use:

Individual intolerance. Panavir® should not be used in patients with allergies to the constituent components of the preparation: glucose, mannose, rhamnose, arabinose, xylose.

lactation period.

Children's age up to 12 years.

Special instructions:

When used at the stage of preparation for pregnancy, it helps to reduce the frequency of reproductive losses in cytomegalovirus and herpesvirus infections. When the solution becomes cloudy, the preparation is considered unsuitable for use.

EFFECT ON ABILITY TO DRIVE VEHICLES AND MECHANISMS

There are no data on the possibility of a negative effect of the preparation on the ability to drive vehicles and carry out potentially hazardous activities that require special attention and speed of psychomotor reactions.

Form release:

Solution for intravenous injection 0.04 mg/ml 5 ampoules of 5ml

Description:

Transparent or slightly opalescent, colorless or odorless liquid with a light brown tinge.

Storage conditions:

To store in the place protected from light at a temperature from 2 to 25 °C.

Guaranteed authenticity and quality:

100% original product from ELLARA LLC (Russian Federation)

Development and production:

ELLARA LLC (Russian Federation)